S
Stately Bio
Advanced ML cell imaging platform driving next-gen regenerative medicines and novel stem cell therapies
About Stately Bio
Stately Bio is at the forefront of regenerative medicine, leveraging its advanced machine learning cell imaging platform to develop life-saving therapies. The company focuses on pioneering novel stem cell-derived treatments, particularly in the realm of liver cell maturation, where it has achieved significant advancements over current standards. Stately Bio collaborates with leading institutions and companies to push the boundaries of cell therapy innovation. Its business model revolves around partnerships and technology licensing, enabling it to generate revenue while advancing its mission to revolutionize cell therapy discovery and manufacturing. The company's unique approach allows for precise measurement of cell identity and behavior without compromising cell viability, setting a new standard in the field.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2022
- Headquarters
- Palo Alto, United States
- Employees
- 6
- Open positions
- None listed
- Dealroom signal
- 63.7/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Stem Cells, Biotech and Pharma, AI Drug Discovery, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SEED✓Equity / VC | May 2025 | $12M | $48M | Tom Berry · Foothill Ventures · Village Global · BoxOne Ventures | ↗ |
Growth signals
Latest recorded traffic for Stately Bio is 1.6K monthly website visits, up 540% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed11 investors entered at this stage
AIX Ventures
Tom Berry
Foothill Ventures
Village Global
BoxOne Ventures
Dimension Capital Management- JWJeremy Wertheimer
Mitsui Global Investment
Jeff Dean
Caffeinated Capital
Axial VC
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Stately Bio on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Stately Bio’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.